References
- 1. Velayos EE, Masi AT, Stevens MB, Shulman LE. The 'CREST' syndrome. Comparison with systemic sclerosis (scleroderma). Arch Intern Med. 1979;139(11):1240-4.
- 2. Merlino G, Germano S, Carlucci S. Surgical management of digital calcinosis in CREST syndrome. Aesthetic Plast Surg. 2013;37(6):1214-9.24142114
- 3. Cutler TS, Reyentovich A. Peripheral phenomena in a woman with calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome-associated pulmonary hypertension. Circulation. 2012;125(9):e413-4.
- 4. Shenavandeh S. Calcinosis universalis in a patient with overlap of scleroderma/dermatomyositis. J Clin Rheumatol. 2012;18(1):57.
- 5. Duzgun N. Cutaneous calcinosis in a patient with limited scleroderma: CREST Syndrome. Eur J Rheumatol. 2017;4(4):305-6.10.5152/eurjrheum.2017.17034
- 6. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
- 7. Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C, et al. Oxidative stress in systemic sclerosis. Mol Cell Biochem. 1999;196(1-2):85-91.
- 8. Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo. 1999;13(3):295-309.
- 9. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.
- 10. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford). 2005;44(5):587-96.15741200
- 11. Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, Schapira D, Markovits D, Rozin A, et al. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Clin Rheumatol. 2007; 26(9):1517-21.10.1007/s10067-007-0613-2
- 12. Johnson JM, Yen TC, Zhao K, Kosiba WA. Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. Am J Physiol Heart Circ Physiol. 2005;288(4):H1573-9.
- 13. Yamazaki F, Sone R, Zhao K, Alvarez GE, Kosiba WA, Johnson JM. Rate dependency and role of nitric oxide in the vascular response to direct cooling in human skin. J Appl Physiol. 2006;100(1):42-50.
- 14. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology. 2002;41(8):843-7.
- 15. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol. 2004;22(3 Suppl 33):S5-13.
- 16. Murrel DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol. 1993;28(1):78-85.10.1016/0190-9622(93)70014-K
- 17. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human diseases. Int J Biochem Cell Biol. 2007;39(1):44-84.10.1016/j.biocel.2006.07.001
- 18. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol. 1988;255(6 Pt 2):H1269-75.
- 19. Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheum J. 2012;6(Suppl 1: M4):87-95.
- 20. Bedard K, Krause KH. The nox family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245-313.
- 21. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44(11):2653-64.